|
Pancreas cancer cases
Case 1: Pancreatic cancer
Name: Herminia Andarnello
Age: 66 years old
Country: Argentina
Reason of consultation:
07/29/2001 She consults due to progressive epigastric
plenitude sensation. She notes abdominal tumefaction.
She presented itchiness and sub-icterical colour.
Personal antecedents:
Without personal antecedents to remark.
Family antecedents:
None to remark.
Present disease antecedents:
She has an ultrasonography done on 07/20/2001 that shows
liver increased in size. Heterogeneous parenchyma due
to multiple solid nodular images from 25 to 63 mm. that
compromise both lobules.
Pancreas in cephalic region. Nodular solid image hipo-ecoic
heterogeneous of 33x29 mm. It presents two internal
micro-calcifications, pancreas body and tail normal
Retro-peritoneum: nodular solid image, hipo-ecoic of
18 mm. of diameter situated in peri-pancreatic region
(lymphadenopathy). Direct Bilirrubine 1.9, Total 9.8
Transaminases: GOT 82, GPT 48
Disease evolution:
11/07/2001: She begun with the medicament with 30 drops
4 times per day on 08/17/2001 until now. From the clinic
point of view conserved appetite, she does not feel
significant annoyances, neither itchiness nor jaundice,
she maintained the same weight from the start when she
had lost much. The ultrasonography of 10/11/2001 shows
necrosis area in liver nodule. She goes on with 30 drops
4 times per day sublingually.
02/06/2002: The patient comes to consult. She has normal
appetite. She does not present epigastric pain. Neither
jaundice nor itchiness. She does not bring new para-clinic.
It is decided to increase the dosage of the medicament
to 50 drops 4 times per day. It is expected to receive
more actualised para-clinic.
08/14/2002: A relative communicates and informs us that
the patient takes the medicament periodically and is
clinically stable. She did not more para-clinic studies
because she herself asked so (the patient). She never
stopped taking the medicament and now we recommend to
increase the dosage to 60 drops 4 times per day.
She passes away in September, 2002, due to her pathology,
remarking the excellent survival she presented and the
graveness of the disease she was suffering from.
Conclusions:
Pancreatic cancer is a pathology of high lethality and
short survival once diagnosed. Of this patient more
than the survival, in time terms, we remark the life
quality she maintained until the end of her disease.
Generally the patients suffering from pancreatic cancer
lead a very impaired survival, with a marked general
repercussion and pains in the solar plexum that many
times lead to the use of radiotherapy as a painkiller,
with the results that many times this has. GREEN SAP
acted in the pancreatic cell level minimizing the suffering
due to its painkiller effect, offering the patient a
worthy and useful survival.
In this patient it shows us another aspect of its action.
By a direct and endorphin liberating action, it eased
the intense pain the patient suffered from, leading
her to the acalmy. It achieved that in an ominous and
grave disease, such as pancreatic cancer, which besides,
causes multiple sufferinGREEN SAP, our patient had a
worthy survival, without pain, with a normal intestinal
movilization, without bilio-hematic derivation, having
a survival that it is not frequent in pancreatic cancer.
This she owes to GREEN SAP.
|
